You are here

The clinical attributes of INVOKANA®, the #1-prescribed SGLT2 inhibitor,* available in an extended-release, fixed-dose combination with metformin1,2

There have been no clinical efficacy studies conducted with INVOKAMET® XR or INVOKAMET® (canagliflozin/metformin HCl). The efficacy and safety of INVOKAMET® XR were assessed in a clinical study as initial combination of canagliflozin and metformin XR coadministered as individual tablets.2,3

Bioequivalence of INVOKAMET® XR to canagliflozin and metformin XR and of INVOKAMET® to canagliflozin and metformin coadministered as individual tablets was demonstrated in healthy subjects.2,3

Initial combination therapy

STUDIED VS METFORMIN XR
26-week initial combination therapy vs metformin XR4

Add-on therapy

STUDIED VS SITAGLIPTIN + METFORMIN
26- and 52-week results of a placebo- and active-controlled study3,5 
  • Canagliflozin 100 mg + metformin and canagliflozin 300 mg + metformin vs placebo + metformin at 26 weeks  
  • Secondary endpoint: canagliflozin 100 mg + metformin and canagliflozin 300 mg + metformin vs sitagliptin 100 mg + metformin at 52 weeks

2 Studies vs Januvia®
Two 52-week studies vs Januvia® 100 mg
  • Study 1: In patients inadequately controlled on metformin + a sulfonylurea3,6
  • Secondary endpoint in study 2: In patients inadequately controlled on metformin5

Studied vs Glimepiride
A 52-week study vs glimepiride, followed by a 52-week extension, in patients inadequately controlled on metformin3,7,8

Studied in Patients With Type 2 Diabetes With Moderate Renal Impairment
A dedicated 26-week placebo-controlled study in patients with moderate renal impairment (eGFR 30 to <50 mL/min/1.73 m2) who were either not on antihyperglycemic (AHA) therapy or were on a stable AHA regimen3,9

Studied in Older Patients With Type 2 Diabetes
A 26-week placebo-controlled study of patients aged 55 to 80 years who were inadequately controlled on diet and exercise alone or in combination with AHA therapy, followed by a 78-week placebo-controlled, double-blind extension in patients inadequately controlled on a stable AHA regimen3,10,11
 
SGLT2=sodium-glucose co-transporter 2.
*Data on file. Janssen Pharmaceuticals, Inc. Based on IMS Health, NPA Weekly, Total Prescriptions, July 1, 2016.
References: 1. Data on file. Janssen Pharmaceuticals, Inc., Titusville, NJ. 2. INVOKAMET® XR [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 3. INVOKAMET® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 4. Rosenstock J, Chuck L, González-Ortiz M, et al. Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-naïve type 2 diabetes. Diabetes Care. 2016;39(3):353-362. 5. Lavalle-González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56:2582-2592. Supplemental tables available at: http://link.springer.com/article/10.1007%2Fs00125-013-3039-1. Accessed September 1, 2016. 6. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial [published correction appears in Diabetes Care. 2013;36(12):4172]. Diabetes Care. 2013;36(9):2508-2515. Supplementary tables available at: http://care.diabetesjournals.org/content/36/9/2508/suppl/DC1. Accessed September 1, 2016. 7. Cefalu WT, Leiter LA, Yoon K-H, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382(9896):941-950. 8. Leiter LA, Yoon K-H, Arias P, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care. 2015;38(3):355-364. 9. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15(5):463-473. 10. Bode B, Stenlöf K, Sullivan D, Fung A, Usiskin K. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract. 2013;41(2):72-84. 11. Bode B, Stenlöf K, Harris S, et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes Obes Metab. 2015;17(3):294-303.